Al-OlaAAbdallahMD

Oncology • Westwood, KS

Hematologic Oncology

Physician

Join to view full profile

Dr. Abdallah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abdallah's full profile

Already have an account?

Office
2650 Shawnee Mission Pkwy
Ms 5003
Westwood, KS 66205
Phone+1 913-588-6078

Fax+1 913-588-3996

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2016
University of Oklahoma School of Community Medicine (Tulsa)Residency, Internal Medicine, 2007 - 2010
University of Jordan Faculty of MedicineClass of 2005

Certifications & Licensure

AR State Medical License 2011 - 2026
KS State Medical License 2016 - 2025
MO State Medical License 2021 - 2025
OK State Medical License 2009 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Publications & Presentations

PubMed

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel
Blood Cancer Journal. 2024-12-05
Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis.
Utkarsh Goel, Danai Dima, James Davis, Nausheen Ahmed, Hira Shaikh
European Journal of Haematology. 2024-12-01
BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma.
Aliya Rashid, William Wesson, Al-Ola Abdallah, Jordan Snyder, Priyanka Venkatesh
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-11

Lectures

SGNBCMA-001: A phase 1 study of SEA‑BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019